Skip to main content
Fig. 3 | Renal Replacement Therapy

Fig. 3

From: Virological response to daclatasvir and asunaprevir combination therapy for chronic hepatitis C virus genotype 1b infection in dialysis patients: a prospective, multicenter study

Fig. 3

Individual patient serum ALT levels at weeks 0, 4, 8, 12, 16, 20, and 24 after the administration of daclatasvir and asunaprevir. Only 1 patient discontinued treatment 12 weeks after commencing therapy due to elevation of serum ALT to 75 IU/l (black arrow). All the other patients continued through week 24

Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us